Table 3.
Safety summary
| Atezolizumab + bevacizumab (n = 48) | Sorafenib (n = 23)a | |
|---|---|---|
| Treatment duration | ||
| Median (range), months | Atezolizumab: 12.5 (0–24) | 4.8 (0–21) |
| Bevacizumab: 11.4 (0–24) | ||
| <3 months, n (%) | Atezolizumab: 8 (17) | 10 (44) |
| Bevacizumab: 8 (17) | ||
| 3 to <6 months, n (%) | Atezolizumab: 3 (6) | 3 (13) |
| Bevacizumab: 5 (10) | ||
| 6 to <9 months, n (%) | Atezolizumab: 8 (17) | 2 (9) |
| Bevacizumab: 9 (19) | ||
| 9 to <12 months, n (%) | Atezolizumab: 3 (6) | 5 (22) |
| Bevacizumab: 3 (6) | ||
| ≥12 months, n (%) | Atezolizumab: 26 (54) | 3 (13) |
| Bevacizumab: 23 (48) | ||
| All-grade AE, any cause, n (%) | 48 (100) | 22 (96) |
| Treatment-related all-grade AE | 43 (90) | 22 (96) |
| Grade 3/4 AE, n (%)b | 31 (65) | 16 (70) |
| Treatment-related grade 3/4 AEc | 22 (46) | 12 (52) |
| Serious AE, n (%) | 25 (52) | 8 (35) |
| Treatment-related serious AE | 10 (21) | 6 (26) |
| Grade 5 AE, n (%) | 4 (8) | 0 |
| Treatment-related grade 5 AE | 1 (2)c | 0 |
| AE leading to withdrawal from any component, n (%) | 12 (25) | 5 (22) |
| AE leading to dose interruption of any study treatment, n (%) | 31 (65) | 9 (39) |
| AE leading to dose modification of sorafenib, n (%)d | 0 | 12 (52) |
AE, adverse event.
a
Safety-evaluable population.
b
Highest grade experienced.
c
Patient experienced a treatment-related grade 5 AE of pneumonia.
d
No dose modification allowed for atezolizumab or bevacizumab.